Drug Type Gene therapy, Hematopoietic stem cell therapy  | 
Synonyms  | 
Target  | 
Action modulators  | 
Mechanism HBG1 modulators(hemoglobin subunit gamma 1 modulators), HBG2 modulators(hemoglobin subunit gamma 2 modulators)  | 
Therapeutic Areas  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhasePreclinical  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Anemia, Sickle Cell | Preclinical | United States   | 01 Feb 2025 | |
| Beta-Thalassemia | Preclinical | United States   | 01 Feb 2025 | 





